Back to the search results

Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg

Baldingerstraße 01
35043 Marburg

Phone: 06421-58-60
Fax: 06421-58-66370
Mail: ed.mg-ku@rm.fgea

  • Number of beds: 938
  • Number of specialist departments: 25
  • Number of inpatient cases: 39.088
  • Number of partial inpatient cases: 973
  • Number of outpatient cases: 378.663
  • Hospital owners: Universitätsklinikum Gießen und Marburg GmbH
  • Type of provider: privat
  • University Hospital
  • Academic teaching hospital
External comparative quality assurance
Further information
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung yes
Bezeichnung
Teilnahme externe Qualitätssicherung no
Quantity performed 39
Exception? No exception
Quantity performed 29
Exception? No exception
Quantity performed 56
Exception? No exception
Quantity performed 25
Exception? No exception
Quantity performed 90
Exception? No exception
Quantity performed 1
Exception? No exception
Overall result forecast presentation: Pending lawsuit
Quantity performed reporting year: 39
Quantity forecast year: 39
Examination by state associations? Pending lawsuit
Exemption? yes
Result of the examination by the federal state authorities? no
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 29
Quantity forecast year: 32
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 56
Quantity forecast year: 53
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 25
Quantity forecast year: 31
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 90
Quantity forecast year: 128
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: Pending lawsuit
Quantity performed reporting year: 24
Quantity forecast year: 22
Examination by state associations? Pending lawsuit
Exemption? yes
Result of the examination by the federal state authorities? no
Transitional arrangement? no
Overall result forecast presentation: no
Quantity performed reporting year: 1
Quantity forecast year: 0
Examination by state associations? no
Exemption? no
Result of the examination by the federal state authorities? no
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 625
Quantity forecast year: 585
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
Overall result forecast presentation: yes
Quantity performed reporting year: 52
Quantity forecast year: 79
Examination by state associations? yes
Exemption? yes
Result of the examination by the federal state authorities? yes
Transitional arrangement? no
No. Explanation
CQ01 Quality assurance measures for inpatient care with the indication abdominal aortic aneurysm
CQ03 Quality assurance measures for the implementation of positron emission tomography (PET) in hospitals for the indications non-small-cell lung cancer (NSCLC) and solid pulmonary nodules
CQ05 Measures for quality assurance in the care of pre-term and full-term neonates – Perinatal Centre LEVEL 1
CQ24 Quality assurance measures for allogeneic stem cell transplantation for multiple myeloma (valid until 30 June 2022)
CQ25 Measures for quality assurance in the performance of minimally invasive heart valve interventions pursuant to Article 136, para. 1, sentence 1, number 2 for hospitals licensed in accordance with Article 108 of the SGB V
CQ27 Guideline on quality assurance measures for inpatient care with bronchoscopic lung volume reduction procedures for severe emphysema (QS Guideline bronchoscopic LVR /QS-RL BLVR)
CQ30 Quality assurance guideline for interstitial LDR brachytherapy for low-risk localized prostate cancer (effective January 8, 2021).
  • Clarifying chat completed: no
  • Clarifying chat not completed: no
  • No participation in clarifying chat: no
  • Notification of non-fulfilment of nursing care not made: yes
Number Group
363 Medical specialists (m/f) , psychological psychotherapists (m/f) and child and adolescent psychotherapists (m/f) who are subject to the obligation to undergo further training*
228 Number of medical specialists (m/f) from no. 1 who have completed a five-year period of further training and are therefore subject to the obligation to provide evidence
225 Number of those persons from no. 2 who have provided proof of further training according to Article 3 of the G-BA regulations
* according to the “Provisions of the Joint Federal Committee for the Further Training of Medical Specialists (m/f), Psychological Psychotherapists (m/f) and Child and Adolescent Psychotherapists (m/f) in Hospitals”

According to Section 4 (2) of the Quality Management Guideline, facilities must provide for the prevention of and intervention in cases of violence and abuse as part of their internal quality management. The aim is to prevent, recognise and respond appropriately to abuse and violence, particularly against vulnerable patient groups such as children and adolescents or people in need of help, and also to prevent it within the facility. The respective procedure is aligned with the size of the facility, the range of services and the patients in order to define customised solutions for sensitising the teams as well as other suitable preventative and interventional measures. These may include information materials, contact addresses, training/education, codes of conduct, recommendations for action/intervention plans or comprehensive protection concepts.

  • Is a protection concept in place? Yes
  • Note on the measure: https://insight.rka/fileadmin/100_RKA/199_Microsites/Compliance/Haltungsgrundsaetze/B_Haltungsgrundsaetze_web.pdf
  • Last review of the measure: 20.02.2022 16:58:05
Gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie haben sich Einrichtungen, die Kinder und Jugendliche versorgen, gezielt mit der Prävention von und Intervention bei (sexueller) Gewalt und Missbrauch bei Kindern und Jugendlichen zu befassen (Risiko- und Gefährdungsanalyse) und – der Größe und Organisationsform der Einrichtung entsprechend – konkrete Schritte und Maßnahmen abzuleiten (Schutzkonzept). In diesem Abschnitt geben Krankenhäuser, die Kinder und Jugendliche versorgen, an, ob sie gemäß § 4 Absatz 2 in Verbindung mit Teil B Abschnitt I § 1 der Qualitätsmanagement-Richtlinie ein Schutzkonzept gegen (sexuelle) Gewalt bei Kindern und Jugendlichen aufweisen.
  • Drug commission

Qualitätsmanagement Konzept Rhönklinikum AG. Für alle Standorte des Universitätsklinikums Gießen und Marburg in Marburg sind Vorgabedokumente zu QM-Prozessen und Dokumente für das Risikomanagement jederzeit verfügbar.

09.11.2022

Qualitätsmanagement Konzept Rhönklinikum AG. Für alle Standorte des Universitätsklinikums Gießen und Marburg in Marburg sind Vorgabedokumente zu QM-Prozessen und Dokumente für das Risikomanagement jederzeit verfügbar.

09.11.2022

Gute Verordnungspraxis

09.09.2020

  • Bereitstellung einer geeigneten Infrastruktur zur Sicherstellung einer fehlerfreien Zubereitung
  • Zubereitung durch pharmazeutisches Personal
  • Anwendung von gebrauchsfertigen Arzneimitteln bzw. Zubereitungen
  • Versorgung der Patientinnen und Patienten mit patientenindividuell abgepackten Arzneimitteln durch die Krankenhausapotheke (z.B. Unit-Dose-System)
  • Maßnahmen zur Vermeidung von Arzneimittelverwechslung
  • Teilnahme an einem einrichtungsübergreifenden Fehlermeldesystem (siehe Kapitel 12.2.3.2)
  • Aushändigung von arzneimittelbezogenen Informationen für die Weiterbehandlung und Anschlussversorgung der Patientin oder des Patienten im Rahmen eines (ggf. vorläufigen) Entlassbriefs
  • Aushändigung von Patienteninformationen zur Umsetzung von Therapieempfehlungen
  • Aushändigung des Medikationsplans
  • bei Bedarf Arzneimittel-Mitgabe oder Ausstellung von Entlassrezepten
The instruments and measures to promote drug therapy safety are presented with a focus on the typical procedures of the medication process in inpatient patient care. A special feature of the medication process in the inpatient environment is the transition management during admission and discharge. The instruments and measures listed below address structural elements, e.g. special IT equipment and work materials, as well as process aspects, such as work descriptions for particularly risky process steps or concepts for securing typical risk situations . In addition, proven measures to avoid or learn from medication errors can be specified. The hospital presents here which aspects it has already dealt with and which measures it has specifically implemented. The following aspects can be presented, if necessary using free text fields:
- Admission to hospital, including anamnesis
; Instruments and measures are presented for determining the old medication (drug history), the subsequent clinical assessment and the switch to the medication available in the hospital (house list), as well as for documenting both the patient's original medication and that for hospital treatment adapted medication.
- Medication process in the hospital
In this context, the following sub-processes are assumed as examples: drug history - prescription - patient information - drug delivery - drug use - documentation - therapy monitoring - result assessment. Instruments and measures for safe medication prescription can be presented, e.g. B. in terms of readability, clarity and completeness of the documentation, but also in terms of area of ​​application, effectiveness, benefit-risk ratio, tolerability (including potential contraindications, interactions, etc.) and resource considerations. Information can also be provided to support reliable medication ordering, delivery and use or administration.
- Discharge
In particular, the measures taken by hospitals can be presented to ensure that information on drug therapy is structured and passed on to doctors and physicians providing further treatment, as well as the appropriate provision of patients with drug information, medication plans and medications. Drug prescriptions are made.
AMTS is the totality of measures to ensure an optimal medication process with the aim of reducing medication errors and thus avoidable risks for patients during drug therapy. A prerequisite for the successful implementation of these measures is that AMTS is practised as an integral part of daily routine in an interdisciplinary and multi-professional approach.
Job
Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Explanation

Training in other healing professions
Comment

Comment

die praktische Ausbildung findet auch am Klinikum statt.

Comment

Comment

Comment

Comment

Comment

In Kooperation mit der DRK Schwesternschaft Marburg wird eine Krankenpflegehilfeausbildung angeboten. Die Ausbildung ist AZAV zertifiziert.

Comment

Comment

Comment

Comment

Comment

Comment

die praktische Ausbildung findet auch am Klinikum statt.

Comment

Comment

Frau Cornelia Opitz

Patientenfürsprecherin im Universitätsklinikum MR

Baldingerstraße 01
35043 Marburg

Phone: 0176 -47754425-
Mail: ed.xmg@ztipo.oc

Frau Anette Wetterau-Ruppersberg

Patientenfürsprecherin (Vertretung)

Baldingerstraße 01
35043 Marburg

Phone: 0171 -9000900-
Mail: ed.enilno-t@ehceukdlaW

Dr. Theresia Jacobi

Patientenfürsprecherin

Baldingerstraße 01
35043 Marburg

Phone: 06421 -164319-
Mail: ed.jtrd@ibocaj.aisereht

Thomas Komm

Patientenfürsprecher

Baldingerstraße 01
35043 Marburg

Phone: 06421 -360341-
Mail: ed.xmg@mmok.samoht

Frau Tanja Bolz

Sekretariat Ärztliche Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66101
Mail: ed.mg-ku@tnemeganamedrewhcseB

Frau Annegret Platt

Ärztliche Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66101
Mail: ed.mg-ku@tnemeganamedrewhcseB

Frau Margitta Zeuner

Angestellte Qualitäts- und Risikomanagement

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-64502
Mail: ed.mg-ku@renueZ.attigraM

Univ.-Prof. Dr. med. Rita Engenhart-Cabillic

Ärztliche Direktorin des Universitätsklinikums Marburg

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66434
Mail: ed.mg-ku@cillibaC-trahnegnE.atiR

Prof. Dr. Thomas Wündisch

Ärztlicher Direktor

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-63900
Mail: ed.mg-ku@hcsidneuW.samohT

Prof. Dr. med Rita Engenhart-Cabillic

Ärztliche Direktorin

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66433
Mail: ed.mg-ku@cillibac-trahnegne.atir

Prof. Dr. med Thomas Wündisch

Ärztlicher Direktor

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-63900
Mail: ed.mg-ku@hcsidneuw.samoht

Frau Tanja Bolz

Beschwerdestelle Ärztliche Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66101
Mail: ed.mg-ku@tnemeganamedrewhcseb

Frau Annegret Platt

Beschwerdestelle Ärztliche Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66101
Mail: ed.mg-ku@tnemeganamedrewhcseb

Baldingerstraße 01
35043 Marburg

Phone: 06421-58-60
Fax: 06421-58-66370
Mail: ed.mg-ku@rm.fgea

Herr Michael Reinecke

Pflegedirektor

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66390
Mail: ed.mg-ku@ekcenieR.leahciM

Jürgen Kleinschmidt

Pflegedirektor ab 2023

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66391
Mail: ed.mg-ku@tdimhcsnielk.negreuj

Herr Kevin Pfaffner

Verwaltungsleiter

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-63524
Mail: ed.mg-ku@renffafp.nivek

Dr. Sylvia Heinis

Kaufmännische Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66004
Mail: ed.mg-ku@sinieH.aivlys

Prof. Dr. Uwe Wagner

Ärztlicher Geschäftsführer am Standort Marburg

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66210
Mail: ed.mg-ku@rengaw.ewu

Prof. Rita Engenhart-Cabillic

Ärztliche Direktorin

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-
Mail: ed.mg-ku@trahnegne.atir

Prof. Dr. Uwe Wagner

Ärztliche Geschäftsführung

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-66311
Mail: ed.mg-ku@fgea

Prof. Dr. med Thomas Wündisch

Ärztlicher Direktor ab 2023

Baldingerstraße 01
35043 Marburg

Phone: 06421 -58-
Mail: ed.mg-ku@hcsidneuw.samoht

IK: 260620431

Location number: 773132000

Old location number: 773132000